M. Vanden Bempt

发表

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.

S. Demeyer, K. Jacobs, J. Cools, 2019, Blood.

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma

S. Ogawa, S. Demeyer, K. Jacobs, 2022, bioRxiv.

Generation of the Fip1l1–Pdgfra fusion gene using CRISPR/Cas genome editing

S. Demeyer, J. Cools, C. D. de Bock, 2016, Leukemia.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

J. Soulier, S. Demeyer, K. Jacobs, 2018, Blood.

EML1–ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model

J. Cools, N. Mentens, P. Vandenberghe, 2018, HemaSphere.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

J. Soulier, S. Demeyer, J. Meijerink, 2018, Cancer discovery.

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

P. Neven, C. Desmedt, D. Lambrechts, 2021, Nature Medicine.

Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified

P. Gaulard, L. de Leval, S. Demeyer, 2021, Nature Communications.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

S. Demeyer, J. Meijerink, E. Radaelli, 2018, Cancer cell.